A patient enrolled in a long-term study of Pfizer's hemophilia drug Hympavzi died after experiencing serious side effects, ...
Zacks.com on MSN
BMY vs AMGN: Which Biotech Stock Is More Resilient Now?
From a price-performance perspective, BMY has fetched slightly better returns than AMGN in the past six months. Shares of ...
Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...
VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy ...
The Pharmacy and Poisons Board (PPB) has raised an alarm concerning the circulation of two critical falsified medications: ...
Novo Nordisk’s oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO ...
The top 10 PharmTech videos of the year cover advanced therapies, high-concentration biologics, major mergers and ...
The "Liraglutide and Semaglutide - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Liraglutide and Semaglutide was valued at US$17.1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback